Trade Syndax Pharmaceuticals, Inc. - SNDX
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. The company was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Latest shares articles

NVIDIA stock forecast: Q3 earnings, CEO transition
US semiconductor giant NVIDIA (NVDA) reported third-quarter fiscal 2027 revenue of $115.8bn on 17 November 2026, up 103% year on year. Explore third-party price targets and technical analysis. Past performance isn't a reliable indicator of future results.
9 hours ago

Take-Two heads into GTA VI launch with a weaker quarter and full-year outlook unchanged
Take-Two’s Q2 Net Bookings came in below guidance, but GTA VI pre-orders are at ‘unprecedented levels’. What the launch could mean for TTWO stock.
13:30, 19 November 2026

Nvidia results preview: what to expect from Q3 after the AI sell-off
Revenue guidance of USD 108bn, a new interim CEO and an AI sell-off: what investors are watching as Nvidia reports its fiscal Q3 2027 results.
12:06, 17 November 2026

What you need to know about Alphabet after the biggest one-day drop in its history – break-down
Google Cloud is growing fast, but AI spending pushed Alphabet’s free cash flow negative. A full break-down of results, valuation, debt and risks for GOOGL
11:53, 13 November 2026
Related News
ACCESS Newswire
ACCESS Newswire
ACCESS Newswire
Public Technologies
ACCESS Newswire
GlobeNewswire
Public Technologies